Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

2020147 citationsJournal Articlehybrid Open Access

Authors

FOENIX-101 (ClinicalTrials.gov, NCT02052778).

Good health and well-being

Published in: Annals of Oncology

Volume 31, Issue 10, pp. 1405-1412

Field-Weighted Citation Impact: 9.01